Fan Liping, Wang Chen, Yu Zhenzhen, Zhan Yihong
Department of Neurology, Xiamen Xinglin Hospital, Xiamen, 361000, China.
Department of Neurology, Fujian Psychiatric Center, Xiamen Xianyue Hospital, Xianyue Hospital Affiliated with Xiamen Medical College, Fujian Clinical Research Center for Mental Disorders, Xianyue Road No. 387, Xiamen, 361000, Fujian, China.
Sci Rep. 2025 Jul 1;15(1):21811. doi: 10.1038/s41598-025-07966-8.
To investigate the clinical features, treatment, and outcomes in cerebral infarction (CI) patients with Sjögrens syndrome (pSS) for novel disease management strategies. A total of 27 patients diagnosed with CI with pSS were divided into the treatment group (12 patients) and non-treatment group (15 patients) according to whether they were treated for pSS in the acute and secondary prevention stage of CI. The related clinicopathological information including age, gender, medical history, experimental data, clinical manifestations, imaging data, treatment, functional recovery and recurrences were retrospectively analyzed. The clinical manifestations of 27 CI patients with pSS varied widely. There were also no significant differences in age, gender, traditional high-risk factors of CI, previous history, experimental data, and short-term nerve functional recovery between the two groups (p > 0.05). After 1 year of treatment, timely treatment of pSS can significantly improve the prognosis, the favorable prognosis (modified Rankin scale ≤ 2) of the treatment and non-treatment groups were 83.3% and 40.0% respectively. The recurrence rate of CI was 0% in the treatment group but 33.3% in the non-treatment group. Compared to the no treatment group. The odds of achieving a favorable prognosis in the treatment group were 7.5 times higher than in the non-treatment group (OR = 7.5, 95% CI: 1.195-47.1). the adjusted odds ratio was 0.113 (95% CI: 0.002-1.214). This indicates an 89% reduction in recurrence odds with treatment. PSS screening is necessary for CI patients. Moreover, prompt pSS treatment administered during the acute and secondary prevention stage of CI with pSS can promote neurologic functional independence and reduce the risk of CI recurrent.
为探究合并干燥综合征（pSS）的脑梗死（CI）患者的临床特征、治疗方法及预后情况，以制定新的疾病管理策略。将27例诊断为合并pSS的CI患者，根据其在CI急性和二级预防阶段是否接受pSS治疗，分为治疗组（12例）和未治疗组（15例）。对相关临床病理信息，包括年龄、性别、病史、实验数据、临床表现、影像资料、治疗情况、功能恢复及复发情况进行回顾性分析。27例合并pSS的CI患者临床表现差异较大。两组在年龄、性别、CI传统高危因素、既往史、实验数据及短期神经功能恢复方面也无显著差异（p＞0.05）。治疗1年后，及时治疗pSS可显著改善预后，治疗组和未治疗组的良好预后（改良Rankin量表评分≤2）分别为83.3%和40.0%。CI复发率治疗组为0%，未治疗组为33.3%。与未治疗组相比，治疗组获得良好预后的几率比未治疗组高7.5倍（OR = 7.5，95%CI：1.195 - 47.1），调整后的优势比为0.113（95%CI：0.002 - 1.214）。这表明治疗使复发几率降低了89%。对CI患者进行PSS筛查很有必要。此外，在合并pSS的CI急性和二级预防阶段及时给予pSS治疗，可促进神经功能独立并降低CI复发风险。
